Copper-Catalyzed Stereospecific C–S Coupling Reaction of Enantioenriched Tertiary Benzylic Amines via in Situ Activation with Methyl Triflate
作者:Wenlong Jiang、Nutao Li、Lihong Zhou、Qingle Zeng
DOI:10.1021/acscatal.8b03032
日期:2018.11.2
1-(thiophen-2-yl)ethanamine), and aminoacid esters containing a benzylamine moiety, are highly efficient substrates, and their chirality is efficiently transferred to the products (94–99% ee). The absolute configurations of the products are predictable and follow the pattern of SN2-type substitutions; an inversion of the absolute configuration of the tertiary amines occurs during the C–S coupling reaction. Not only
Organotin(IV) compounds 2-(Me2NCHR)C6H4(SnR′R″Br) with a fixed s-cis arrangement of the chiral carbon and tin centers. Crystal structure of 2-(Me2NCHBut)C6H4SnMePhBr
作者:Johann T.B.H. Jastrzebski、Jaap Boersma、Gerard van Koten
DOI:10.1016/0022-328x(91)80037-k
日期:1991.8
A series of novel pentacoordinate triorganotin bromides SnR′R″Br[C6H4CH(R)NMe2-2] have been synthesized and characterized in which R is H, Me, Et, i-Pr or t-Bu. The crystalstructure of one of these compounds (R = t-Bu, R′ = Me and R″ = Ph) has been determined. The tin center has a distored trigonal-bipyramidal coordination geometry. The organic ligands occupy the equatorial sites, while the more electronegative
Polynuclear aryl-copper species and neutral aryl-cuprates with a chiral-CH(Me)NMe2 ortho substituent
作者:Gerard van Koten、Johann T.B.H. Jastrzebski
DOI:10.1016/0040-4020(89)80084-5
日期:1989.1
GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
申请人:NEUROCRINE BIOSCIENCES, INC.
公开号:EP1255738B1
公开(公告)日:2012-03-07
THERAPEUTIC COMPOUNDS AND USES THEREOF
申请人:GENENTECH, INC.
公开号:US20170275289A1
公开(公告)日:2017-09-28
The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein ring A, R
1
, R
3
, R
4
, R
5
, and each R
e
have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.